Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

• Status: RECRUITING
• Trial end date: 2027-12-01

Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

• Phase: PHASE3

Details

• Lead Sponsor: Revolution Medicines, Inc.
• Treatments: 130-nm albumin-bound paclitaxel; Fluorouracil; Gemcitabine; Irinotecan; irinotecan sucrosofate; Leucovorin; Oxaliplatin